This fall, it may not be possible for many parents to have a healthy child younger than age 5 immunized against COVID.

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.

The Food and Drug Administration is considering revoking Pfizer Inc.’s authorization to sell its Covid vaccine for children under the age of 5, a move that would leave healthy kids with no available ...

Those who invested in Pfizer three years ago and hung on are not thrilled. They would have done much better with a simple S&P ...

The top public health officials during Trump's first term praised mRNA vaccines. In the second term, officials seem to be retreating from them.

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain s GSK and Germany s CureVac $740 ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Pfizer › Pfizer (NYSE: PFE) has been a terrible investment over the past three years. Revenue and earnings have generally moved in the wrong direction, as the company has been unable to follow up on ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

A Fallen Giant Pfizer (NYSE:PFE) has been a bitter pill for investors to swallow. Down 19% from its 52-week high of $30.43 per share, PFE stock has plummeted over 50% in the past three years, a stark ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...